Table 1.
Characteristics of the overall study cohort and by adjunctive surgical resection status.
| Variables | Total n = 58 (%) |
Surgical resection n = 27 (%) |
No surgical resection n = 31 (%) |
p-Valuea |
|---|---|---|---|---|
| Age, yearsb | 31 (24–42) | 26 (23–39) | 35 (28–45) | 0.01 |
| Male sex | 33 (57) | 14 (52) | 19 (61) | 0.65 |
| BMI (kg/m2) at follow-upb | 24 (21–27) | 23 (21–26) | 24 (21.5–26.9) | 0.89 |
| Tobacco use | 23 (40) | 10 (37) | 13 (42) | 0.91 |
| Alcohol use | 11 (19) | 3 (11) | 8 (26) | 0.28 |
| Diabetes | 5 (9) | 1 (4) | 4 (13) | 0.44 |
| Hepatitis C | 4 (7) | 1 (4) | 3 (10) | 0.71 |
| TB case definition | 0.02 | |||
| New | 24 (41) | 16 (59) | 8 (26) | |
| Prior TB | 34 (59) | 11 (41) | 23 (74) | |
| Baseline CXR findings | ||||
| Multilobar | 36 (62) | 14 (52) | 22 (71) | 0.22 |
| Bilateral | 25 (43) | 7 (26) | 18 (58) | 0.03 |
| Bilateral cavities | 13 (22) | 1 (4) | 12 (39) | <0.01 |
| Follow-up CXR findings (n = 54) | ||||
| Multiple nodules | 22 (38) | 0 | 22 (71) | <0.01 |
| Cavity | 12 (21) | 0 | 12 (39) | <0.01 |
| Fibrosis | 30 (52) | 5 (19) | 25 (81) | <0.01 |
| Bronchiectasis | 7 (12) | 0 | 7 (23) | 0.02 |
| Pleural adhesions | 10 (17) | 4 (15) | 6 (19) | 0.73 |
| Drug resistance | ||||
| Pre XDR or XDR | 25 (43) | 17 (63) | 8 (26) | 0.01 |
| Surgery type | ||||
| Lobectomy | 10 (37) | |||
| Segmentectomy | 15 (56) | |||
| Thoracoplasty | 2 (7) | |||
| Treatment duration | ||||
| Monthsb | 23.0 (21–25) | 25 (22–27) | 22 (21–24) | 0.02 |
| Follow-up timec | ||||
| Monthsb | 41.2 (29–50) | 39 (33–46) | 43 (29–51) | 0.53 |
| Pulmonary function | ||||
| FVC (ml)b | 3520 (2760–4780) | 3985 (3078–4953) | 3300 (2575–4455) | 0.07 |
| FEV1 (ml)b | 2600 (1870–3837) | 2990 (2070–3900) | 2050 (1515–3520) | 0.10 |
| Peak expiratory flowb | 75 (52–91) |
BMI, body mass index; TB, tuberculosis; CXR, chest X-ray; XDR, extensively drug-resistant; FVC, forced vital capacity; FEV, forced expiratory volume.
a
Two-sided Chi-square and t-test statistics used.
b
Values are given as the median (interquartile range).
c
Time from end of treatment to follow-up study visit.